The Company and subsidiary companies must comply with the conditions stipulated in the investment promotional privileges. Revenues of the Company and subsidiary companies for the years 2010 and 2009 can be separated between the promoted and non-promoted operation as follows: (Unit: Baht)
Consolidated financial statements Promoted operation Non-promoted operation
2010 Revenue from hospital operations Other income Total revenues
724,543,943 724,543,943
2009
2010
2009
Total
2010
2009
1,711,976,146 22,788,085,015 19,884,998,507 23,512,628,958 21,596,974,653 538,585,597 377,028,055 538,585,597 377,028,055 1,711,976,146 23,326,670,612 20,262,026,562 24,051,214,555 21,974,002,708 (Unit: Baht)
Promoted operation
Revenue from hospital operations Other income Total revenues
2010
2009
5,931,522 5,931,522
-
Separate financial statements Non-promoted operation
2010
2009
Total
2010
2009
7,213,783,094 6,879,286,497 7,219,714,616 6,879,286,497 1,300,783,121 1,164,376,346 1,300,783,121 1,164,376,346 8,514,566,215 8,043,662,843 8,520,497,737 8,043,662,843
32. Financial instruments The Company and its subsidiaries’ financial instruments, which are defined in Thai accordance with Accounting Standard No. 107 “Financial Instruments: Disclosure and Presentation�, principally comprise the financial assets and liabilities mentioned in Note 4.16 to financial statements. The financial risks associated with these financial instruments and how they are managed is described below.
32.1 Financial risk management The Company and its subsidiaries are exposed to risk arising from changes in market interest rates and foreign currency exchange rates, and from nonperformance of contractual obligation by counterparties in the future. The subsidiaries do not use derivative instruments, while the Company uses derivative instruments as and when they consider appropriate, to manage such risks. Neither the Company nor subsidiaries hold or issue derivative financial instruments for speculative or trading purposes.